WHO ICTRP trial
Evaluating the effect of Fluoxetine on symptoms and quality of life of patients…
IRCT138805012159N2 · Iranian Registry of Clinical Trials (IRCT) · Not Recruiting
Key facts
| Trial ID | IRCT138805012159N2 |
|---|---|
| Public title | Evaluating the effect of Fluoxetine on symptoms and quality of life of patients with moderate to severe irritable bowel syndrome in adults. |
| Scientific title | Evaluating the effect of Fluoxetine on symptoms and quality of life of patients with moderate to sever irritable bowel syndrome in adults. |
| Primary sponsor | Isfahan University of Medical Sciences |
| Registry | Iranian Registry of Clinical Trials (IRCT) |
| Recruitment status | Not Recruiting |
| Study type | interventional |
| Phase | 2 |
| Countries | Iran (Islamic Republic of) |
| Conditions | Irritable bowel syndrome. Irritable bowel syndrome;Irritable bowel syndrome |
| Interventions | Intervention 1: Fluoxetine 20 milligram, capsule, daily plus placebo capsule, oral, daily for 12 weeks. Intervention 2: 2 placebo capsules, oral, daily for 12 weeks. Intervention 3: Fluoxetine, 40 milligram, 20 miligram capsules twice… |
| Registration date | May 29, 2010 |
| Target size | 180 |
| Registry page | irct.behdasht.gov.ir |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: